Indoco Remedies secures USFDA nod for Lofexidine Tablets 0.18 mg

Read Also:Indoco Remedies bags USFDA tentative nod for Canagliflozin and Metformin Hydrochloride Tablets for type 2 diabetes mellitus

This product is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment.

As per IQVIA Health data, the sales of the product are around USD 15.59 million with an expected growth of 38%.

Commenting on the achievement, Ms. Aditi Panandikar, Managing Director said, “We are extremely pleased with this development as this strengthens our position in the US market, driving us closer to expanding our reach in the US.”

Indoco is a fully integrated, research-oriented pharmaceutical company. The Company’s turnover is US$ 212 million.

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, with a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,35,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions and a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexidin, MCBM 69, Methycal, Dropizine, Noxa, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

Read Also:Indoco Remedies gets USFDA okay for Pregabalin capsules